(E)-4-Ethyl-2-[(Z)-hydroxyimino]-5-nitro-hex-3-enoic acid amide | 92454-60-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (E)-4-Ethyl-2-[(Z)-hydroxyimino]-5-nitro-hex-3-enoic acid amide
• 英文别名: FK 409；(+/-)-(E)-ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexeneamide；(E,2Z)-4-Ethyl-2-hydroxyimino-5-nitro-hex-3-enamide；(E,2Z)-4-ethyl-2-hydroxyimino-5-nitrohex-3-enamide
• CAS: 92454-60-9；138472-01-2
• 化学式: C₈H₁₃N₃O₄
• 分子量: 215.209
• InChiKey: MZAGXDHQGXUDDX-JSRXJHBZSA-N

物化性质

• 溶解度：
  DMF：>34mg/mL； DMSO：>20mg/mL；乙醇：>36mg/mL； PBS pH 7.2：>2.2 mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  122
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2928000090

反应信息

• 作为反应物：
  描述：

  (E)-4-Ethyl-2-[(Z)-hydroxyimino]-5-nitro-hex-3-enoic acid amide 生成 (E,2Z)-4-ethyl-2-methoxyimino-5-nitrohex-3-enamide
  参考文献：
  名称：

  OKAMOTO, MASANORI;IWAMI, MORITA;TAKASE, SHIGEHIRO;UCHIDA, ITSUO;UMEHARA, +

  摘要：

  DOI：
• 作为产物：
  描述：

  (2E,4E)-4-乙基己-2,4-二烯酰胺 生成 (E)-4-Ethyl-2-[(Z)-hydroxyimino]-5-nitro-hex-3-enoic acid amide
  参考文献：
  名称：

  OKAMOTO, MASANORI;IWAMI, MORITA;TAKASE, SHIGEHIRO;UCHIDA, ITSUO;UMEHARA, +

  摘要：

  DOI：

文献信息

• [EN] COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT DE TROUBLES MÉTABOLIQUES
  申请人：NUSIRT SCIENCES INC

  公开号：WO2018058109A1

  公开（公告）日：2018-03-29

  Methods and compounds useful for reducing, treating, preventing, or sustaining the reduction of a metabolic disease or disorder are provided herein. Also provided herein are compositions and kits for practicing any of the methods described herein.

  本文提供了用于减少、治疗、预防或维持代谢性疾病或紊乱的方法和化合物。本文还提供了用于实施本文中描述的任何方法的组合物和工具包。
• Stabilizer for 4-ethyl-2-hydroxyimino5-nitro-3-hexenamide-containing preparation and stabilizing method therefor
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0452697A1

  公开（公告）日：1991-10-23

  A stabilizer for 4-ethyl-2-hydroxyimino-5-nitro-3-hexenamide represented by the following chemical formula (I) or a salt thereof acceptable as drug or drug containing as pharmacologically active ingredient a compound represented by a chemical formula (I) , in particular, (± )-(E)-4-ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexenamide or salt/s thereof acceptable as drugs, a stabilizing method by the use thereof and drugs containing such stabilizer and stabilized thereby.

  以下化学式(I)代表的4-乙基-2-羟基亚氨基-5-硝基-3-己烯酰胺或其盐的稳定剂，可作为药物或含有化学式(I)代表的化合物作为药理活性成分的药物，特别是(±)-(E)-4-乙基-2-[(E)-羟基亚氨基]-5-硝基-3-己烯酰胺或其盐/可作为药物的稳定剂，使用这种稳定剂的稳定方法以及含有这种稳定剂并因此得到稳定的药物。
• Nitric oxide donor for the treatment of chronic fatigue syndrome
  申请人：Bergen Teknologioverføring AS

  公开号：EP2805730A1

  公开（公告）日：2014-11-26

  The present invention relates in a first aspect to a nitric oxide donor for use in the treatment of chronic fatigue syndrome also known as myalgic encyphalomyelitis. In particular, the present invention relates to the use of a pharmaceutical composition containing a nitric oxide donor for the treatment of chronic fatigue syndrome/myalgic encyphalomyelitis in a subject afflicted with said disease. In a further aspect, the present invention relates to a combination of a nitric oxide donor with a B-cell depleting agent for use in the treatment of chronic fatigue syndrome. Said combination may be provided in form of a kit comprising pharmaceutically effective dosages of said compounds. Further, the present invention relates to a method for treating chronic fatigue syndrome comprising the step of administering nitric oxide donor to a subject afflicted therewith.

  本发明的第一个方面涉及一种用于治疗慢性疲劳综合征（又称肌痛性脑脊髓炎）的一氧化氮供体。特别是，本发明涉及一种含有一氧化氮供体的药物组合物，用于治疗慢性疲劳综合征/肌痛性脑脊髓炎患者的慢性疲劳综合征/肌痛性脑脊髓炎。 在另一方面，本发明涉及一氧化氮供体与B细胞消耗剂的组合物，用于治疗慢性疲劳综合征。所述组合物可以试剂盒的形式提供，试剂盒中包含药学上有效剂量的所述化合物。此外，本发明还涉及一种治疗慢性疲劳综合征的方法，该方法包括向慢性疲劳综合征患者施用一氧化氮供体的步骤。
• Compositions and methods for treating metabolic disorders
  申请人：NuSirt Sciences, Inc.

  公开号：US10344002B2

  公开（公告）日：2019-07-09

  Methods and compounds useful for reducing, treating, preventing, or sustaining the reduction of a metabolic disease or disorder are provided herein. Also provided herein are compositions and kits for practicing any of the methods described herein.

  本文提供了用于减少、治疗、预防或持续减少代谢性疾病或紊乱的方法和化合物。本文还提供了用于实施本文所述任何方法的组合物和试剂盒。
• New nitro aliphatic compounds, process for preparation thereof and use thereof
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0113106B1

  公开（公告）日：1986-05-14